The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1039
November 6, 1998
View Complete Issue         Table of Contents 2019 
Capecitabine and Trastuzumab for Metastatic Breast Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Capecitabine and Trastuzumab for Metastatic Breast Cancer
November 6, 1998 (Issue: 1039)
Trastuzumab (Herceptin - Genentech), a recombinant 'humanized' monoclonal antibody (rhuMAb) that binds to a protein encoded by the oncogene HER2, and capecitabine (ka pe site' a been; Xeloda - Roche), an oral pro-drug for 5-fluorouracil, have been...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Capecitabine and Trastuzumab for Metastatic Breast Cancer
Article code: 1039b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.